Source comparison
CJC-1295 No DAC & Ipamorelin: Research Comparison Table
CJC-1295 no DAC + Ipamorelin Pulsatile, 2.5–3.2× baseline AUC Minimal over 8–12 weeks Long-term metabolic studies, tissue remodeling, lipolysis dynamics Moderate (twice-daily dosing, timing-dependent) Best choice for studies requiring sustained GH elevation wi
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC + Ipamorelin
- Pulsatile, 2.5–3.2× baseline AUC
- Minimal over 8–12 weeks
- Long-term metabolic studies, tissue remodeling, lipolysis dynamics
- Moderate (twice-daily dosing, timing-dependent)
- Best choice for studies requiring sustained GH elevation without rhythm disruption—synergy is reproducible and well-documented
- CJC-1295 with DAC
- Sustained elevation, 1.8–2.4× baseline AUC
- Moderate after 4–6 weeks
- Short-term IGF-1 elevation studies
- Low (weekly dosing)
- Simpler dosing but loses pulsatility and shows receptor blunting—acceptable for protocols under 4 weeks
- Ipamorelin monotherapy
- Pulsatile, 1.2–1.5× baseline AUC
- Minimal
- Acute GH response studies, ghrelin pathway research
- Low (single daily dose)
- Effective for isolated ghrelin receptor studies but lacks GHRH-mediated amplification—predictable but modest effect
- CJC-1295 no DAC monotherapy
- Pulsatile, 1.4–1.7× baseline AUC
- GHRH receptor dynamics, endogenous pulse amplification
- Moderate (timing-dependent)
- Reliable GHRH analog but misses ghrelin pathway—combination with Ipamorelin produces measurably better results
- GHRP-2 or GHRP-6
- Pulsatile but with cortisol/prolactin co-release
- Low to moderate
- Broad secretagogue studies where hormonal crosstalk is acceptable
- Moderate (multiple daily doses)
- Less selective than Ipamorelin—cortisol elevation complicates interpretation in metabolic studies